Thiazolidinediones: Effects on Insulin Resistance and the Cardiovascular System

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2007 Oct 2

PMID 17906687

Citations 61

Authors

C E Quinn

P K Hamilton

C J Lockhart

G E McVeigh

Affiliations

Soon will be listed here.

Abstract

Thiazolidinediones (TZDs) have been used for the treatment of hyperglycaemia in type 2 diabetes for the past 10 years. They may delay the development of type 2 diabetes in individuals at high risk of developing the condition, and have been shown to have potentially beneficial effects on cardiovascular risk factors. TZDs act as agonists of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) primarily in adipose tissue. PPAR-gamma receptor activation by TZDs improves insulin sensitivity by promoting fatty acid uptake into adipose tissue, increasing production of adiponectin and reducing levels of inflammatory mediators such as tumour necrosis factor-alpha (TNF-alpha), plasminogen activator inhibitor-1(PAI-1) and interleukin-6 (IL-6). Clinically, TZDs have been shown to reduce measures of atherosclerosis such as carotid intima-media thickness (CIMT). However, in spite of beneficial effects on markers of cardiovascular risk, TZDs have not been definitively shown to reduce cardiovascular events in patients, and the safety of rosiglitazone in this respect has recently been called into question. Dual PPAR-alpha/gamma agonists may offer superior treatment of insulin resistance and cardioprotection, but their safety has not yet been assured.

Citing Articles

Metabolic syndrome in patients with schizophrenia: Underlying mechanisms and therapeutic approaches (Review).

Manta A, Georganta A, Roumpou A, Zoumpourlis V, Spandidos D, Rizos E Mol Med Rep. 2025; 31(5).

PMID: 40017113 PMC: 11894597. DOI: 10.3892/mmr.2025.13479.

Harnessing Pharmacomultiomics for Precision Medicine in Diabetes: A Comprehensive Review.

Dhieb D, Mustafa D, Hassiba M, Alasmar M, Elsayed M, Musa A Biomedicines. 2025; 13(2).

PMID: 40002860 PMC: 11853021. DOI: 10.3390/biomedicines13020447.

AbaComplex Enhances Mitochondrial Biogenesis and Adipose Tissue Browning: Implications for Obesity and Glucose Regulation.

Sagliocchi S, Schiano E, Acampora L, Iannuzzo F, Cicatiello A, Miro C Foods. 2025; 14(1.

PMID: 39796338 PMC: 11720057. DOI: 10.3390/foods14010048.

Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review.

Zheng H, Sechi L, Navarese E, Casu G, Vidili G Cardiovasc Diabetol. 2024; 23(1):346.

PMID: 39342178 PMC: 11439309. DOI: 10.1186/s12933-024-02434-5.

Inflammation causes insulin resistance in mice via interferon regulatory factor 3 (IRF3)-mediated reduction in FAHFA levels.

Yan S, Santoro A, Niphakis M, Pinto A, Jacobs C, Ahmad R Nat Commun. 2024; 15(1):4605.

PMID: 38816388 PMC: 11139994. DOI: 10.1038/s41467-024-48220-5.

References

Marfella R, DAmico M, Di Filippo C, Baldi A, Siniscalchi M, Sasso F . Increased activity of the ubiquitin-proteasome system in patients with symptomatic carotid disease is associated with enhanced inflammation and may destabilize the atherosclerotic plaque: effects of rosiglitazone treatment. J Am Coll Cardiol. 2006; 47(12):2444-55. DOI: 10.1016/j.jacc.2006.01.073. View

Blaschke F, Spanheimer R, Khan M, Law R . Vascular effects of TZDs: new implications. Vascul Pharmacol. 2006; 45(1):3-18. DOI: 10.1016/j.vph.2005.11.009. View

Asano T, Wakisaka M, Yoshinari M, Iino K, Sonoki K, Iwase M . Peroxisome proliferator-activated receptor gamma1 (PPARgamma1) expresses in rat mesangial cells and PPARgamma agonists modulate its differentiation. Biochim Biophys Acta. 2000; 1497(1):148-54. DOI: 10.1016/s0167-4889(00)00054-9. View

Bath P . The effect of nitric oxide-donating vasodilators on monocyte chemotaxis and intracellular cGMP concentrations in vitro. Eur J Clin Pharmacol. 1993; 45(1):53-8. DOI: 10.1007/BF00315350. View

Takagi T, Yamamuro A, Tamita K, Yamabe K, Katayama M, Mizoguchi S . Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J. 2003; 146(2):E5. DOI: 10.1016/S0002-8703(03)00146-7. View

Goldberg R, Kendall D, Deeg M, Buse J, Zagar A, Pinaire J . A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005; 28(7):1547-54. DOI: 10.2337/diacare.28.7.1547. View

Long S, Pekala P . Lipid mediators of insulin resistance: ceramide signalling down-regulates GLUT4 gene transcription in 3T3-L1 adipocytes. Biochem J. 1996; 319 ( Pt 1):179-84. PMC: 1217752. DOI: 10.1042/bj3190179. View

Denton R, Brownsey R, Belsham G . A partial view of the mechanism of insulin action. Diabetologia. 1981; 21(4):347-62. DOI: 10.1007/BF00252681. View

Roden M, Price T, Perseghin G, Petersen K, Rothman D, Cline G . Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest. 1996; 97(12):2859-65. PMC: 507380. DOI: 10.1172/JCI118742. View

10.

St John Sutton M, Rendell M, Dandona P, Dole J, Murphy K, Patwardhan R . A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care. 2002; 25(11):2058-64. DOI: 10.2337/diacare.25.11.2058. View

11.

Berger J, Akiyama T, Meinke P . PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci. 2005; 26(5):244-51. DOI: 10.1016/j.tips.2005.03.003. View

12.

Lehmann J, Moore L, Wilkison W, Willson T, Kliewer S . An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995; 270(22):12953-6. DOI: 10.1074/jbc.270.22.12953. View

13.

Liu H, Tao L, Gao E, Lopez B, Christopher T, Willette R . Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion. Cardiovasc Res. 2004; 62(1):135-44. DOI: 10.1016/j.cardiores.2003.12.027. View

14.

Barnes P, Karin M . Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997; 336(15):1066-71. DOI: 10.1056/NEJM199704103361506. View

15.

Randle P, Garland P, Hales C, Newsholme E . The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963; 1(7285):785-9. DOI: 10.1016/s0140-6736(63)91500-9. View

16.

Iuorno M, Nestler J . Insulin-lowering drugs in polycystic ovary syndrome. Obstet Gynecol Clin North Am. 2001; 28(1):153-64. DOI: 10.1016/s0889-8545(05)70191-1. View

17.

Calnek D, Mazzella L, Roser S, Roman J, Hart C . Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol. 2003; 23(1):52-7. DOI: 10.1161/01.atv.0000044461.01844.c9. View

18.

Kahn S, Haffner S, Heise M, Herman W, Holman R, Jones N . Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355(23):2427-43. DOI: 10.1056/NEJMoa066224. View

19.

Desvergne B, Wahli W . Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev. 1999; 20(5):649-88. DOI: 10.1210/edrv.20.5.0380. View

20.

Ogihara T, Rakugi H, Ikegami H, Mikami H, Masuo K . Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens. 1995; 8(3):316-20. DOI: 10.1016/0895-7061(95)96214-5. View